Authors:
M.V. Zhuravlev 1.2 , A.B. Prokofiev 1.2 , V.V. Arkhipov 1 , S.Yu. Serebrova 1.2 , G.I. Gorodetskaya 1.2 , O.A. Demidova 1
1 FSBI “Scientific Center for Expertise of Medical Application” of the Ministry of Health of Russia, Moscow, Russia;
2 FGAOU VO "First Moscow State Medical University named after THEM. Sechenov "Ministry of Health of Russia (Sechenov University), Moscow, Russia
Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova 2020, T. 120, No. 3, P. 87-91
Summary:
an analysis of the clinical efficiency and safety of the use of ethylmethylhydroxypyridine of succinate (Mexidol) in a complex of rehabilitation measures in patients who have undergone ischemic stroke (AI). It is shown that with the terminal use of the drug in patients, restoration of neurological functions is improved, regression of neurological deficiency and cognitive disorders, including improving memory, reducing the manifestation of asthenic syndrome, increasing the level of socio-household adaptation, and improving the psychoemotional state of patients, a decrease in spasticity, increasing spasticity, and increasing the motor and speech activity, praxis, reliable elimination of ignoring syndrome. In patients who have suffered AI, there was a decrease in the blood level of total cholesterol and low-density С-lipoproteins, a decrease in the severity of hypercoagulation. The results of the studies convincingly showed the feasibility of using ethylmethylhydroxypyridine of succinate (Mexidol) at all stages of restoration treatment of patients who suffered AI. Keywords : ethylmethylhydroxypyrididine succinate, Mexidol, rehabilitation, recovery, stroke.